Skip to main content
Log in

Update on radiation therapy in patients with Cushing’s disease

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Introduction

Radiation therapy is an important therapy for patients with Cushing’s disease who are not in remission or relapse after transsphenoidal pituitary surgery and are not considered surgical candidates. The development of stereotactic radiation therapy, using gamma knife, linear accelerators or proton beam based methods, has enabled selective radiation delivery to the target while minimizing exposure of healthy tissues. In patients whose tumors are sufficiently distant from the optic apparatus, stereotactic radiation therapy can be delivered in a single session, a procedure termed radiosurgery, which significantly improves patient convenience.

Methods

Original articles on radiation therapy in Cushing's disease, published during the past 12 months (2013–2014), were identified and pertinent data extracted.

Results

Recent studies have reported on the outcomes of patients with Cushing’s disease who received mostly stereotactic radiation therapy. While tumor control has been excellent, biochemical remission was less consistently achieved. Some studies suggested that stereotactic radiation may lead to biochemical remission faster than conventional radiation therapy. In addition, retrospective data have suggested that withdrawing medical therapy around the time stereotactic radiation therapy is administered might lead to a faster biochemical response. Regardless of the radiation therapy method, biochemical recurrences may develop and these patients are at long-term risk of developing anterior hypopituitarism and require lifelong periodic endocrine follow-up. Other, less frequent complications may include cranial neuropathies, secondary tumor formation or temporal lobe necrosis. It is plausible that complications may be less frequent after stereotactic radiation therapy, but this requires confirmation.

Conclusions

Radiation therapy is an effective second line therapy in patients with Cushing’s disease. Ongoing refinements in delivery of radiation therapy are anticipated to lead to improved patient outcomes, but long-term follow-up data, including adequate control groups, are needed to fully investigate this possibility.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M (2008) Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 93:2454–2462

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Swearingen B, Biller BM, Barker FG 2nd, Katznelson L, Grinspoon S, Klibanski A, Zervas NT (1999) Long-term mortality after transsphenoidal surgery for Cushing disease. Ann Intern Med 130:821–824

    Article  CAS  PubMed  Google Scholar 

  3. Tritos NA, Biller BM (2014) Cushing’s disease. Handb Clin Neurol 124:221–234

    Article  PubMed  Google Scholar 

  4. Tritos NA, Biller BM, Swearingen B (2011) Management of Cushing disease. Nat Rev Endocrinol 7:279–289

    Article  CAS  PubMed  Google Scholar 

  5. Loeffler JS, Shih HA (2011) Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab 96:1992–2003

    Article  CAS  PubMed  Google Scholar 

  6. Sheehan JP, Xu Z, Salvetti DJ, Schmitt PJ, Vance ML (2013) Results of gamma knife surgery for Cushing’s disease. J Neurosurg 119:1486–1492

    Article  PubMed  Google Scholar 

  7. Budyal S, Lila AR, Jalali R, Gupta T, Kasliwal R, Jagtap VS, Bandgar T, Menon P, Shah NS (2014) Encouraging efficacy of modern conformal fractionated radiotherapy in patients with uncured Cushing’s disease. Pituitary 17:60–67

    Article  PubMed  Google Scholar 

  8. Grant RA, Whicker M, Lleva R, Knisely JP, Inzucchi SE, Chiang VL (2014) Efficacy and safety of higher dose stereotactic radiosurgery for functional pituitary adenomas: a preliminary report. World Neurosurg 82:195–201

    Article  PubMed  Google Scholar 

  9. Wilson PJ, Williams JR, Smee RI (2014) Cushing’s disease: a single centre’s experience using the linear accelerator (LINAC) for stereotactic radiosurgery and fractionated stereotactic radiotherapy. J Clin Neurosci 21:100–106

    Article  CAS  PubMed  Google Scholar 

  10. Wattson DA, Tanguturi SK, Spiegel DY, Niemierko A, Biller BM, Nachtigall LB, Bussiere MR, Swearingen B, Chapman PH, Loeffler JS, Shih HA (2014) Outcomes of proton therapy for patients with functional pituitary adenomas. Int J Radiat Oncol Biol Phys 90:532–539

    Article  PubMed  Google Scholar 

  11. Mehta GU, Sheehan JP, Vance ML (2013) Effect of stereotactic radiosurgery before bilateral adrenalectomy for Cushing’s disease on the incidence of Nelson’s syndrome. J Neurosurg 119:1493–1497

    Article  PubMed  Google Scholar 

  12. Assie G, Bahurel H, Coste J, Silvera S, Kujas M, Dugue MA, Karray F, Dousset B, Bertherat J, Legmann P, Bertagna X (2007) Corticotroph tumor progression after adrenalectomy in Cushing’s disease: a reappraisal of Nelson’s syndrome. J Clin Endocrinol Metab 92:172–179

    Article  CAS  PubMed  Google Scholar 

  13. Wilson PJ, Williams JR, Smee RI (2014) Nelson’s syndrome: single centre experience using the linear accelerator (LINAC) for stereotactic radiosurgery and fractionated stereotactic radiotherapy. J Clin Neurosci 21:1520–1524

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

Dr. Tritos has served as the PI of research grants to MGH from Ipsen and Pfizer and has received occasional consulting honoraria from Pfizer and Corcept. Dr. Biller has served as the PI of research grants to MGH from Novartis and Cortendo and received occasional consulting honoraria from Novartis and Cortendo.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Nicholas A. Tritos.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tritos, N.A., Biller, B.M.K. Update on radiation therapy in patients with Cushing’s disease. Pituitary 18, 263–268 (2015). https://doi.org/10.1007/s11102-014-0615-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-014-0615-4

Keywords

Navigation